Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012 - Wikidata - awgldk - TriplyDB

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012

http://www.wikidata.org/entity/Q28552890

about

Knowledge, Beliefs and Attitudes of Patients and the General Public towards the Interactions of Physicians with the Pharmaceutical and the Device Industry: A Systematic Review.Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics.Unhealthy marketing of pharmaceutical products: An international public health concern.Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts

P2860

Q36111491-CE3820BA-AAA0-4A7C-A206-525C4B4BC02B Q41991279-3B73E30C-1EA3-4545-AEEC-EBF580B2EC1F Q48859735-F7BBC73D-9C90-4262-8E5D-6F8AB6D5C37E Q57806288-692C551C-2E8D-48CA-AF13-E1A7D5AFB249

P2860

Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012

http://www.wikidata.org/entity/Q28552890

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@ast

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@en

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@nl

type

label

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@ast

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@en

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@nl

prefLabel

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@ast

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@en

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@nl

P1433

Q28552890-CC06629D-2BE3-4562-98FF-0965420B2C76

P1476

Q28552890-B23D6F8A-E7C6-42F0-B386-D1AEE34DB379

P2860

Q28552890-022CDE58-4F4E-4CF0-835C-8A8525B596C7

Q28552890-0230733D-5EC0-41D4-9113-E885697D1E35

Q28552890-1EFE84F1-971F-4EBB-8583-A6B1A0CCA94C

Q28552890-25D88FB1-40F7-4F2C-B037-438414EE98C2

Q28552890-2C889AFC-05B0-4CC0-AD77-17DB1BC835A6

Q28552890-2E85AFE3-92C9-44B0-A59F-20B0BC4E5324

Q28552890-3B9099B5-D116-4B18-AE28-6EA3B9A960C6

Q28552890-3D5E56BE-998A-4D1E-8D6E-F227B7EF3086

Q28552890-4217BCAF-A466-495D-B259-72012F723567

Q28552890-4D06B22F-D08C-4C9A-ADA0-364D29D36221

P304

Q28552890-941CE226-0259-40EE-979F-0AF7CAAF9D36

P31

Q28552890-C63E17C9-83FC-45A5-BEB7-9E01D4E1DBC3

P3181

Q28552890-B36DBEB7-FDFD-4034-8B49-2A1D4150A81D

P356

Q28552890-59C16F5F-D9AC-4C68-BDD7-3FB516BC7F9C

P407

Q28552890-23A65775-1BB0-4946-94D3-A4F40CAE3CE5

P433

Q28552890-EAF0B9C1-F833-4E0B-BF92-1B213DD87FAB

P478

Q28552890-7091BB9A-730B-42E6-BC55-8C1CB22AA5B1

P50

Q28552890-29D6A582-CB6A-4E3C-B022-53058A6E9AD1

Q28552890-35C9CB16-CC8E-4500-8112-0D831E9D13D5

Q28552890-87F66D16-130A-418F-B981-DD42470C2227

P577

Q28552890-E13662D7-33EA-4E45-9278-EE22F82F57DB

P5875

Q28552890-D20C2CD2-CE2D-4B0F-BB35-BFA94DB9F44D

P698

Q28552890-138554F2-90D0-4836-927F-AA5A71446C6F

P932

Q28552890-C5113BCC-9C4F-4DC4-8B61-3D32202B21A6

P3181

P356

JOURNAL.PMED.1001945

P1433

P1476

Pharmaceutical Industry Off-la ...... f Practice Authority 2003-2012

@en

P2860

Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration

Ethical and legal framework and regulation for off-label use: European perspective

Valvular heart disease associated with fenfluramine-phentermine

U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey

Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation

Characteristics and impact of drug detailing for gabapentin

Off-label promotion, on-target sales

Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints

Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation

Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States.

P304

e1001945

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3912180

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.1001945

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Vilhelmsson

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

291970720

http://www.w3.org/2001/XMLSchema#string

P698

26812151

http://www.w3.org/2001/XMLSchema#string

P932

4727894

http://www.w3.org/2001/XMLSchema#string